SBI Securities Co. Ltd. Invests $544,000 in Solventum Co. (NYSE:SOLV)

SBI Securities Co. Ltd. bought a new position in Solventum Co. (NYSE:SOLV) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 8,241 shares of the company’s stock, valued at approximately $544,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in SOLV. State of Alaska Department of Revenue lifted its stake in shares of Solventum by 7.2% in the third quarter. State of Alaska Department of Revenue now owns 16,075 shares of the company’s stock worth $1,120,000 after buying an additional 1,085 shares in the last quarter. Janney Montgomery Scott LLC lifted its position in Solventum by 9.8% during the third quarter. Janney Montgomery Scott LLC now owns 42,931 shares of the company’s stock valued at $2,993,000 after purchasing an additional 3,848 shares during the period. Harbor Capital Advisors Inc. bought a new position in Solventum during the third quarter valued at approximately $2,624,000. Van ECK Associates Corp lifted its position in Solventum by 53.9% during the third quarter. Van ECK Associates Corp now owns 36,694 shares of the company’s stock valued at $2,660,000 after purchasing an additional 12,847 shares during the period. Finally, Robeco Institutional Asset Management B.V. lifted its position in Solventum by 29.0% during the third quarter. Robeco Institutional Asset Management B.V. now owns 27,826 shares of the company’s stock valued at $1,940,000 after purchasing an additional 6,260 shares during the period.

Solventum Stock Down 1.5 %

Shares of SOLV stock opened at $78.95 on Wednesday. Solventum Co. has a 12 month low of $47.16 and a 12 month high of $85.92. The stock has a market cap of $13.64 billion and a P/E ratio of 28.71. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45. The company has a 50 day simple moving average of $73.02 and a two-hundred day simple moving average of $70.33.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. Mizuho increased their price objective on shares of Solventum from $70.00 to $82.00 and gave the company a “neutral” rating in a research report on Monday. Wells Fargo & Company increased their price objective on shares of Solventum from $73.00 to $75.00 and gave the company an “equal weight” rating in a research report on Friday, February 28th. Bank of America increased their price objective on shares of Solventum from $80.00 to $85.00 and gave the company a “neutral” rating in a research report on Wednesday, February 26th. Piper Sandler increased their price objective on shares of Solventum from $75.00 to $84.00 and gave the company a “neutral” rating in a research report on Friday, February 28th. Finally, Morgan Stanley increased their price objective on shares of Solventum from $60.00 to $73.00 and gave the company an “equal weight” rating in a research report on Monday, November 11th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $78.86.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.